| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 82 | 17.8x | 17.8x | Top tier | |
Growth | 88 | 35.1% | 7.1% | Top tier | |
Quality | 43 | 6.3% | 4.5% | Around median | |
Safety | 42 | 4.1x | 2.6x | Around median | |
Capital Return | 86 | 6.11% | 2.12% | Top tier | |
Momentum | 61 | 14.6% | 2.9% | Around median | |
Sentiment | 72 | 9 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Amcor plc operates globally in consumer product packaging solutions, and its revenue model is based on selling flexible and rigid packaging and products such as bottles, closures, pumps, and specialized packaging solutions. Its core portfolio is concentrated in nutrition, healthcare, beauty and wellness, and specialty applications, including the protein, liquids, foodservice, and pet care categories; the six focus categories represented more than 50% of core portfolio sales in Q4 fiscal 2026.
In Q4 fiscal 2026, revenue reached $6.4 billion, gross profit was $1.3 billion, and net income was $389 million, equivalent to a calculated gross margin of approximately 20.3% and a net margin of approximately 6.1%. Net sales increased 26% year over year, while net income reversed from a loss of $39 million in the comparable period, and adjusted earnings per share reached $1.23, up 23%.
Fiscal 2026 revenue reached approximately $23.5 billion, gross profit was $4.7 billion, net income was $1.1 billion, and earnings per share according to EDGAR filings were approximately $2.38, while management reported adjusted earnings per share of $4.02, up 13%. The core portfolio generated annual sales of $21 billion and an operating profit margin of 12.7%, while its quarterly sales reached $5.7 billion out of a total of $6.4 billion; Flexible Packaging Solutions segment sales increased 16% and Rigid Packaging Solutions segment sales increased 35% on a constant-currency basis, driven primarily by the inclusion of the Berry business and the pass-through of higher raw material costs.
The analyst consensus is Buy, with an average price target of $48.38, a high of $56, and a low of $43; the average is approximately 5% below the 52-week range high of $50.94, while the high target exceeds that peak. The breadth of the targets compared with the 52-week range of $36.25 to $50.94 indicates differing estimates regarding the pace of achieving Berry synergies and the recovery in cash flow, and the provided data does not allow the assessment to be based on a fixed price-to-earnings multiple.
Figures in the text are as of 2026-08-28; the live price is shown at the top of the page.
Amcor's revenue reached approximately $6.4 billion, up 26% year over year, and net income was $389 million compared with a loss of $39 million in the comparable period. Growth came primarily from the Berry acquisition, an additional month of earnings from the acquired business, and the pass-through of higher raw material costs. The company also achieved $115 million in merger synergies during the quarter, and volumes improved by approximately 200 basis points compared with Q3 fiscal 2026.
Amcor achieved synergies of $285 million during fiscal 2026, including $115 million in Q4, exceeding the first-year target by approximately 10%. Management maintains a total target of $650 million over three years, with the necessary actions and most of the target expected to be completed by the end of 2027. In addition to cost reductions, the company secured growth contracts with an annual value of approximately $140 million against an initial target of $280 million over three years.
Management expects adjusted earnings per share of between $1.80 and $1.90 during the six-month period ending December 31, 2026. The outlook includes a positive impact of between $0.13 and $0.21 from synergies and operating performance, offset by a negative impact of between $0.10 and $0.12 from higher interest and taxes, and a negative impact of $0.04 from divestitures. The company assumes that volumes will be flat or only slightly higher, with leverage expected to be between 3.5 and 3.6 times at the end of the period.
Automated analysis for informational purposes only — not investment advice.
Free cash flow reached $1.3 billion, approximately $200 million below the company's guidance range. The shortfall came primarily from higher inventory and accounts receivable due to the Middle East conflict, alongside accelerated integration spending, after funding $290 million of restructuring and integration costs related to Berry. Management targets the recovery of more than $500 million within 12 months, with approximately $100 million to $300 million expected to be recovered during the six-month period ending December 31, 2026.
Foodservice, pet care, and protein recorded strong volume growth, while liquids and beauty and wellness remained stable. In protein, management said Moda equipment began supporting new configurations that drive related consumables sales. Healthcare volumes declined because of lower-margin medical categories, but the company recorded progress in higher-margin pharmaceutical products such as nasal, ophthalmic, and inhalation devices, alongside a contract related to GLP-1 products and expansion in India and Asia.
The company passed through approximately $280 million of higher costs to customers in Q4 fiscal 2026, offsetting most of the inflation it faced. The adjusted operating profit margin for flexible packaging was 15.1%, while the rigid packaging margin increased by 180 basis points to 12.3%. The outlook for the six-month period ending December 31, 2026 assumes that pricing will continue to offset inflation, with the outcome remaining linked to developments in resin supplies and the Middle East conflict.
